摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-溴代异戊酸甲酯 | 26330-51-8

中文名称
2-溴代异戊酸甲酯
中文别名
2-溴-3-甲基丁酸甲酯;2-溴异戊酸甲酯
英文名称
methyl 2-bromo-3-methylbutanoic ester
英文别名
methyl 2-bromoisovalerate;methyl 2-bromo-3-methylbutyrate;2-bromo-3-methylbutyric acid methyl ester;methyl 2-bromo-3-methylbutanoate
2-溴代异戊酸甲酯化学式
CAS
26330-51-8
化学式
C6H11BrO2
mdl
MFCD00798412
分子量
195.056
InChiKey
CKDTYRDFEIGXNO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    177°C (rough estimate)
  • 密度:
    1.3520

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    9
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.833
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2915900090
  • 储存条件:
    2-8°C

SDS

SDS:03086727dfac40b028b47955def5648c
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Methyl 2-bromoisovalerate
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 2-bromoisovalerate
CAS number: 26330-51-8

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H11BrO2
Molecular weight: 195.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途:用于有机合成中间体、制冷剂等。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-溴代异戊酸甲酯盐酸甲酸间氯过氧苯甲酸 作用下, 以 1,2-二氯乙烷 为溶剂, 反应 20.0h, 生成 methyl (2S,3R)-2-ethyl-3-[(2S)-1-methoxy-3-methyl-1-oxobutan-2-yl]oxirane-2-carboxylate
    参考文献:
    名称:
    吡咯里西啶生物碱。Axillaridine 的 Necic 酸组分 4-Carboxy-4-ethyl-3-hydroxy-2-isopropyl-4-butanolide 的所有立体异构体的合成和绝对构型
    摘要:
    4-羧基-4-乙基-3-羟基-2-异丙基-4-丁内酯的所有立体异构体 (4a,b–7a,b) 都已合成,这是 axillaridine 的 necic 酸成分。甲基(E)-(S)-(+)-2-乙基-4-甲氧基羰基-5-甲基-2-己烯酸(12a)被转化为γ-内酯酸、4a(2S、3S、4S)、5a( 2S,3R,4R) 和 5b (2R,3S,4S),通过一系列反应:用间氯过苯甲酸环氧化,在氯化锡 (IV) 存在下用丙酮处理,用甲酸酸性水解,和用氢氧化钡碱水解。类似地,(R)-(-)-对映异构体(12b)也被转化为γ-内酯酸4b(2R、3R、4R)、5b和5a。随后,(E)-(S)-(+)-4-羧基-2-乙基-5-甲基-2-己烯酸(13a)及其(R)-(-)-对映异构体(13b)用氯甲基甲基酯化在三乙胺存在下生成相应的双(甲氧基甲基)酯(26a 和 26b)。用高锰酸钾氧化 26a 并随后进行酸性水解,得到
    DOI:
    10.1246/bcsj.65.1761
  • 作为产物:
    描述:
    2-溴代异戊酸硫酸 作用下, 以 甲醇 为溶剂, 生成 2-溴代异戊酸甲酯
    参考文献:
    名称:
    Substituted triazolinones, triazolinethiones, and triazolinimines as
    摘要:
    已披露了新的取代三唑酮,三唑硫酮和三唑亚胺化合物,这些化合物可用作血管紧张素II拮抗剂。这些化合物具有一般式:##STR1## 其中G为R.sup.1或##STR2##
    公开号:
    US05411980A1
点击查看最新优质反应信息

文献信息

  • Discovery of 4-Substituted Pyrrolidone Butanamides as New Agents with Significant Antiepileptic Activity
    作者:Benoit M. Kenda、Alain C. Matagne、Patrice E. Talaga、Patrick M. Pasau、Edmond Differding、Bénédicte I. Lallemand、Anne M. Frycia、Florence G. Moureau、Henrik V. Klitgaard、Michel R. Gillard、Bruno Fuks、Philippe Michel
    DOI:10.1021/jm030913e
    日期:2004.1.1
    role in its antiepileptic properties. Using this novel molecular target, we initiated a drug-discovery program searching for ligands with significant affinity to LBS with the aim to characterize their therapeutic potential in epilepsy and other central nervous system diseases. We systematically investigated the various positions of the pyrrolidone acetamide scaffold. We found that (i) the carboxamide moiety
    (S)-α-乙基-2-氧代吡咯烷乙酰胺2(左乙拉西坦,Keppra,UCB SA)是吡乙酰胺的结构类似物,最近已被批准作为成人难治性部分发作的附加治疗药物。由于独特的作用机理,该药物似乎具有显着的功效和高耐受性。后者涉及2的脑特异性结合位点(左乙拉西坦结合位点为LBS),可能在其抗癫痫特性中起主要作用。使用这种新型分子靶标,我们启动了一项药物发现计划,以寻找对LBS具有显着亲和力的配体,以表征其在癫痫和其他中枢神经系统疾病中的治疗潜力。我们系统地研究了吡咯烷酮乙酰胺支架的各个位置。我们发现(i)2上的羧酰胺部分对于亲和力是必不可少的;(ii)在100个不同的侧链中,优选的羧酰胺取代α是具有(S)-构型的乙基;(iii)2-氧吡咯烷环优于哌啶类似物或无环化合物;(iv)内酰胺环的3或5位取代降低了LBS亲和力;(v)内酰胺环被小的疏水基团4-取代改善了体外和体内的效力。已显示在4位上取代的6种有趣的候选物在体内比2种更有效。
  • Stereoselective dehydrobromination of alkyl α-Brα-Cl-carboxylates
    作者:Luca Forti、Franco Ghelfi、Ugo M. Pagnoni
    DOI:10.1016/0040-4039(95)00416-a
    日期:1995.4
    (Z)-Alkyl α-Cl-α,β-unsaturated esters are prepared in excellent yields by stereoselective dehydrobromination of alkyl α-Br-α-Cl-carboxylates with LiClLi2CO3 in dimethylformamide.
    (Z)-烷基α-Cl-α,β-不饱和酯是通过在二甲基甲酰胺中用LiCl 3 Li 2 CO 3对烷基α-Br-α-Cl-羧酸酯进行立体选择性脱氢溴化而制得的。
  • Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
    申请人:Chang Han-Ting
    公开号:US20070135385A1
    公开(公告)日:2007-06-14
    Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject.
    吲哚和与吲哚相关的化合物、组合物以及方法被披露。发明中的这些化合物作为磷脂酶抑制剂非常有用。发明中的这些化合物和组合物用于治疗动物受试者中的磷脂酶相关状况,例如胰岛素相关、体重相关和/或胆固醇相关状况。
  • INDOLE DERIVATIVES AS CRAC MODULATORS
    申请人:Alam Muzaffar
    公开号:US20110071150A1
    公开(公告)日:2011-03-24
    Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 and R 4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).
    公式I的化合物: 或其药用可接受的盐, 其中R1、R2、R3和R4按本文定义。还公开了制造这些化合物的方法以及使用这些化合物治疗与钙释放激活钙通道(CRAC)相关疾病的用途。
  • Studies on antidiabetic agents. IX. A new aldose reductase inhibitor, AD-5467, and related 1,4-benzoxazine and 1,4-benzothiazine derivatives: Synthesis and biological activity.
    作者:Hiroyuki TAWADA、Yasuo SUGIYAMA、Hitoshi IKEDA、Yujiro YAMAMOTO、Kanji MEGURO
    DOI:10.1248/cpb.38.1238
    日期:——
    N-Acetic acid derivatives (I) of 2-substituted 1, 4-benzoxazines and benzothiazines were designed and synthesized for evaluation as new aldose reductase inhibitors. In general, 3-thioxo derivatives were more potent inhibitors of aldose reductase from human placenta in vitro than the corresponding 3-oxo derivatives. While many compounds (I) were not very effective in inhibiting sorbitol accumulation in the rat sciatic nerve in vivo, the 3-thioxo compounds bearing an isopropyl group at the 2-position showed highly potent activity in the in vivo assay. Compound 46 (AD-5467) was selected from this series as a candidate for further development.
    N-乙酸衍生物(I)的2-取代基1,4-苯并恶嗪和苯并噻嗪被设计合成,以评估其作为新型醛糖还原酶抑制剂的潜力。一般而言,3-硫代羰基衍生物在体外对人胎盘醛糖还原酶的抑制活性比相应的3-氧代衍生物更强。虽然许多化合物(I)在体内对大鼠坐骨神经山梨醇积累的抑制作用并不十分有效,但在体内试验中,2-位带有异丙基的3-硫代羰基化合物显示出极强的活性。从这一系列中选出化合物46(AD-5467)作为进一步开发的候选药物。
查看更多